A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 332 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive July 27, 2023 Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with... June 9, 2026 Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal... September 7, 2022 FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer December 15, 2025 Load more HOT NEWS Teen’s Innovative “SMART Armour” Protects Breast Cancer Patients from Radiation “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain... Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive... Men’s skin cancer rates increase by 50% over decade
